Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 15)
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial Of AXS-12 In Narcolepsy
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in SYMPHONY (Study Evaluating a
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen’s Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 13)
10 Biggest Price Target Changes For Monday
Barclays raised Affirm Holdings, Inc. (NASDAQ: AFRM) price target from $85 to $115. Affirm shares rose 37% to $93.00 in pre-market trading.
HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Lowers Price Target to $180
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $225 to $180.
Why Is Axsome Therapeutics (AXSM) Stock Shooting Higher On Monday?
Axsome Therapeutics Inc (NASDAQ:AXSM) stock is rising in premarket due to an update for its US marketing application seeking approval for…
